Correction: Transcriptome profiling analysis reveals that CXCL2 is involved in anlotinib resistance in human lung cancer cells.

Correction to: BMC Med Genomics 12, 38 (2019) 10.1186/s12920-019-0482-y

Following publication of the original article [1], the authors identified an error in Fig. 4 of their article. The Fig. 4 replacement is published in this correction article.

Fig. 4

CXCL2 is involved in anlotinib resistance in NCI-H1975 cells. A, B CXCL2 (50 ng/ml) and anlotinib (4 μg/ml) were performed on NCI-H1975 cells, alone or together for 24 h. Migration rate was examined by wound healing scratch assay. Bars = mean ± SD, n = 3, *P < 0.05, **P < 0.01. Scale bar, 100 μm. C, D CXCL2 (100 ng/ml) and anlotinib (2 μg/ml) were performed on NCI-H1975 cells, alone or together, for 24 h. Invasion rate was analyzed based on transwell assays. Bars = mean ± SD, n = 3, **P < 0.01, ***P < 0.001. Scale bar, 100 μm. E, F NCI-H1975 cells were exposed to CXCL2 (100 ng/ml) and anlotinib (4 μg/ml), alone or together for 24 h. Ratio of total apoptosis and early apoptosis were examined based on flow cytometric detection. Data are shown as mean ± SD, n = 3, *P < 0.05, **P < 0.01, ***P < 0.001